Home
About Us
Membership
Member Biography

Member Biography

Jennifer King, MD

Jennifer King, M.D.

Phone: (317) 944-0920, Patient issues/appointments

Faculty appointments

Assistant Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate member, Experimental and Developmental Therapeutics

Neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer with selective bladder sparingCTO-HCRN-GU20-444

Retrospective Analysis of Patients with Urothelial Carcinoma at Indiana University: 1990-2033 IUSCCC-0835

Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumorCTO-IUSCCC-0894

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)CTO-HCRN-GU22-587

PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]CTO-A031704

A phase II trial evaluating the efficacy of Cabozantinib in the treatment of incurable patients with refractory germ cell tumorsCTO-IUSCCC-0752

Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma - STRIKECTO-A032201

A multimodality exercise intervention for patients with relapsed metastatic germ-cell tumor undergoing high dose chemotherapy with stem cell transplant: Assessing implementation outcomes and early efficacyHEMO-CC-GU-IUSCCC-0914

EXACT: Randomized Phase II Trial of XL092 in Combination with Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCCTO-HCRN-GU22-595

Headlines & highlights

Indiana research leads to life-extending treatment for prostate cancer (Apr. 2025)

#ResearchCuresCancer

Support Our Research